Ebola virus

Ebola may leave retinal scarThe Ebola virus may leave a retinal scar specific to the disease, according to researchers. “The distribution of these retinal scars or lesions provides the first observational evidence that the virus enters the eye via the optic nerve to reach the retina in a similar way to West Nile virus,” said Dr Paul Steptoe of the Royal Liverpool Hospital, in a press release.
Why humans are making epidemics worseNearly every year there seems to be some new epidemic that crops up, creating healthcare crises and worldwide panic. Robert Kalayjian, MD, director of infectious diseases at MetroHealth Medical Center in Cleveland, says these epidemics are becoming more common, and he explained the implications for public health during a session at SECO 2016.
Giving weight to worrisome reportsPeople—like my neighbor and I—for centuries, have tended to give too much weight to negative news stories and gloomy predictions. Hence my resolution for 2016 to pay less attention to the doomsayers and pour more drinks for my friends.
Ebola and the eye
Ebola and the eyeThe unexpected discovery of viable Ebola virus in the eye of a patient who had recovered from the systemic disease has strengthened efforts to learn more about ophthalmic and systemic complications of Ebola survivors and has translated to management and follow-up strategies in West Africa.
HHS, drugmaker partner on Ebola drugThe U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and Regeneron Pharmaceuticals in Tarrytown, New York, are partnering to develop a novel Ebola virus treatment.
BioCryst receives $12 million for Ebola drug developmentBioCryst Pharmaceuticals, Durham, North Carolina, was awarded a $12 million contract with the U.S. Department of Health and Human Services for the development and manufacture of its small molecule, BCX4430, for the prevention of Ebola virus reproduction.
Ebola's lessons
Ebola's lessonsEnvisioning a public health threat, managed care recently notched up its readiness for an Ebola outbreak in the United States. Valuable lessons emerged from the latest effort, adding to the knowledge gleaned from other epidemics, such as the HIV/AIDS and SARS viruses and the bird flu.
Ebola treatment in America
Ebola treatment in AmericaWhat is it like to care for patients with Ebola? Clinical pharmacists share what they’ve learned.
Emergency Ebola test authorized for useFDA issued an Emergency Use Authorization (EUA) for LightMix Ebola Zaire rRT-PCR Test for Ebola disease. The test can be used in West Africa and the United States.
NIH reports first experimental Ebola vaccine produces immune responseThe first experimental Ebola vaccine has been shown to be safe and prompt an immune response in results from a National Institutes of Health (NIH) phase 1 clinical trial. The vaccine produced immune system responses and was well tolerated in the whole study cohort of 20 healthy adults.